The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Headline
The Food and Drug Administration today announced it is accelerating regulatory action on a new class of psychedelic-based therapies, following an April 18…
Headline
Americans across 43 states enrolled in health plans from the nation’s four largest commercial health insurers face potential disparities in finding in-network…
Headline
The cigarette smoking rate among U.S. adults dropped to 9.9% in 2024, the lowest level ever recorded, according to a report by the New England Journal of…
Headline
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use disorders, including for alcohol…
Headline
The Substance Abuse and Mental Health Services Administration announced March 6 that it will award $69.1 million in grants for mental health and suicide…
Headline
The Food and Drug Administration March 5 issued a request for information seeking public comments on potential new standards for in-home opioid disposal…